NLS drug-2

Nykode Therapeutics has announced key conclusions from the updated analysis from the Phase 2 VB-C-02 trial. The trial investigates the use of Nykode’s wholly-owned off-the-shelf therapeutic cancer vaccine candidate VB10.16 in combination with Roche’s checkpoint inhibitor atezolizumab in patients with recurrent or metastatic HPV16-positive cervical cancer. The updated results, which closely mirror the previously reported […]

Cantargia has reported new data highlighting the potential of the CAN10 antibody, currently in phase I clinical development, as therapy in systemic sclerosis. All signaling systems targeted by CAN10 (IL-1, IL-33 and IL-36) were found to be highly upregulated in patient skin biopsies. These cytokines induce fibrosis in skin fibroblasts isolated from patients, and this […]

Atrogi has announced the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D). “This full phase 1a/b data readout is exactly what we were aiming for, with primary and secondary safety-endpoints met. This puts us in a strong position to progress our ground-breaking small […]

In November 2023 SynAct Pharma reported that during the evaluation of the data from part A of the RESOLVE study, a four-week dose range study of resomelagon (AP1189) in rheumatoid arthritis patients with an inadequate response to methotrexate treatment, issues were identified that needed further evaluation and initiated an audit of the study by an […]

ACELYRIN has announced that the global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met its primary endpoint with high statistical significance. Positive long-term data from a Phase 2b clinical trial in hidradenitis suppurativa (HS) were also announced. In the Phase 2b/3 PsA trial the primary endpoint of ACR50 at week 16 was […]

The combined treatment of UV1 with ipilimumab and nivolumab showed similar clinical benefits as treatment with ipilimumab and nivolumab alone, meaning the primary and secondary endpoints of the study were not met. Ultimovacs has reported results from the Phase II clinical trial, INITIUM, evaluating the company’s therapeutic cancer vaccine candidate UV1 as first-line treatment in […]